综述 |
|
|
|
|
免疫佐剂在肿瘤免疫疗法中的应用进展 * |
钱颖,钱晨,白晓庆,王晶晶() |
南京中医药大学药学院 南京 210023 |
|
Application of Adjuvant in Cancer Immunotherapy |
QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing() |
College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China |
引用本文:
钱颖,钱晨,白晓庆,王晶晶. 免疫佐剂在肿瘤免疫疗法中的应用进展 *[J]. 中国生物工程杂志, 2020, 40(3): 96-103.
QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing. Application of Adjuvant in Cancer Immunotherapy. China Biotechnology, 2020, 40(3): 96-103.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.1906018
或
https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I3/96
|
[1] |
Antje T, Maximilian K, Rebekka W , et al. Immune monitoring of cancer patients prior to and during CTLA-4 or PD-1/PD-L1 inhibitor treatm ent. Biomedicines, 2018,6(1):26-39.
|
[2] |
Soares K C, Rucki A A, Wu A A , et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. Journal of Immunotherapy, 2015,38(1):1-11.
|
[3] |
司春枫, 鲁美钰, 周玲 , 等. 肿瘤疫苗免疫策略研究进展. 现代肿瘤医学, 2016,24(15):2478-2482.
|
|
Si C F, Lu M Y, Zhou L , et al. Research progress of tumor vaccine strategy. Journal of Modern Oncology, 2016,24(15):2478-2482.
|
[4] |
Holay N, Kim Y, Lee P , et al. Sharpening the edge for precision cancer immunotherapy: targeting tumor antigens through oncolytic vaccines. Frontiers in Immunology, 2017,8:800.
|
[5] |
Klevorn L E, Teague R M . Adapting cancer immunotherapy models for the real world. Trends in Immunology, 2016,37(6):354-363.
|
[6] |
Littman D . Releasing the brakes on cancer immunotherapy. Cell, 2015,162(6):1186-1190.
|
[7] |
高花, 韩勇, 翟晓鑫 , 等. MHC分子抗原递呈机制的研究进展. 生命科学, 2017,29(5):450-461.
|
|
Gao H, Han Y, Zhai X X , et al. The research progress of antigen presentation by MHC molecules, Chinese Bulletin Life Sciences, 2017,29(5):450-461.
|
[8] |
Yarchoan M, Johnson B A, Lutz E R , et al. Targeting neoantigens to augment antitumour immunity. Nature Reviews Cancer, 2017,17(4):209-222.
|
[9] |
Vermaelen K . Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunology, 2019,10:8.
|
[10] |
Hu Z, Ott P A, Wu C J . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nature reviews Immunology, 2018,18(3):168-182.
|
[11] |
Zevini A, Olagnier D, Hiscott J . Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends in Immunology, 2017,38(3):194-205.
|
[12] |
Vasou A, Sultanoglu N, Goodbourn S , et al. Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses. Viruses, 2017,9(7):186.
|
[13] |
Zhu G M, Vishwasrao H D, Jacobson O , et al. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy. Nature Communications, 2017,8(1):1482.
|
[14] |
Wang C, Ye Y, Hu Q , et al. Tailoring biomaterials for cancer immunotherapy: emerging trends and future outlook. Advanced Materials, 2017,29(29):1606036.
|
[15] |
Song W, Das M, Xu Y , et al. Leveraging biomaterials for cancer immunotherapy: targeting pattern recognition receptors. Materials Today Nano, 2019,5:100029.
|
[16] |
Bianchi F, Pretto S, Tagliabue E , et al. Exploiting poly (I: C) to induce cancer cell apoptosis. Cancer Biology & Therapy, 2017,18(10):747-756.
|
[17] |
Bianchi F, Pretto S, Tagliabue E , et al. Exploiting poly(I:C) to induce cancer cell apoptosis. Cancer Biology & Therapy, 2017,18(10):747-756.
|
[18] |
Fan L, Zhou P, Hong Q , et al. Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation. OncoImmunology, 2019,8(6):1-12.
|
[19] |
Azuma M, Takeda Y, Nakajima H , et al. Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology, 2016,5(8):e1188244.
|
[20] |
Vivas I, Itibarren K, Lozano T , et al. Therapeutic effect of irreversible electroporation in combination with Poly-ICLC adjuvant in preclinical models of hepatocellular carcinoma. Journal of Vascular and Interventional Radiology, 2019,30(7):1098-1105.
|
[21] |
Fakhari A, Nugent S, Elvecrog J , et al. Thermosensitive gel based formulation for intra-tumoral delivery of Toll-like receptor 7/8 dual agonist, MEDI9197. Journal of Pharma-ceutical Sciences, 2017,106(8):2037-2045.
|
[22] |
Meng Z, Lu M . RNA interference-induced innate immunity, off-target effect, or immune adjuvant. Frontiers in Im-munology, 2017,8:331-337.
|
[23] |
Dowling D J . Recent advances in the discovery and delivery of TLR7/8 agonists as vaccine adjuvants. Immunohorizons, 2018,2(6):185-197.
|
[24] |
Rodell C B, Arlauckas S P, Cuccarese M F , et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nature Biomedical Engineering, 2018,2(8):578-588.
|
[25] |
Kayraklioglu N, Scheiermann J, Alvord W G , et al. Effect of calcium carbonate encapsulation on the activity of orally administered CpG oligonucleotides. Molecular Therapy Nu-cleic Acids, 2017,8:243-249.
|
[26] |
徐宁, 杜锐, 李健明 , 等. 新型免疫增强剂CpG ODN的研究进展. 安徽农业科学, 2019,47(6):8-10.
|
|
Xu N, Du R, Li J M , et al. Research progress of the new immunopotentiator CpG ODN. Journal of Anhui Agricultural Sciences, 2019,47(6):8-10.
|
[27] |
Sato T, Shimosato T, Ueda A , et al. Intrapulmonary delivery of CpG microparticles eliminates lung tumors. Molecular Cancer Therapeutics, 2015,14(10):2198-2205.
|
[28] |
Tian Y, Li M, Yu C , et al. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo. Oncotarget, 2017,8(28):45951-45964.
|
[29] |
Kuai R, Sun X, Yuan W , et al. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy. Journal of Controlled Release, 2018,28:131-139.
|
[30] |
Shetab Boushehri M A, Lamprecht A . TLR4-Based immunotherapeutics in cancer: a review of the achievements and shortcomings. Molecular Pharmaceutics, 2018,15(11):4777-4800.
|
[31] |
Moon S H, Shin E C, Noh Y W , et al. Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine. Vaccine, 2015,33(38):4762-4769.
|
[32] |
Huimin Y, Tomomori K, Papawee S , et al. Targeting C-type lectin receptors for cancer immunity. Frontiers in Immunology, 2015,6:408.
|
[33] |
Yang R, Xu J, Xu L , et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. Acs Nano, 2018,12(6):5121-5129.
|
[34] |
Hung T H, Chiu Y H, Chan Y L , et al. Prophylactic administration of fucoidan represses cancer metastasis by inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in Lewis tumor-bearing mice. Marine Drugs, 2015,13(4):1882-1900.
|
[35] |
Chiang C S, Lin Y J, Lee R , et al. Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy. Nature Nanotechnology, 2018,13(8):746-754.
|
[36] |
De G P, Govers C, Wichers H J , et al. Consumption of β-glucans to spice up T cell treatment of tumors: a review. Expert Opinion on Biological Therapy, 2018,18(10):1023-1040.
|
[37] |
Liang F, Lindgren G, Sandgren K J , et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Science Translational Medicine, 2017,9(393):2094-2103.
|
[38] |
Lebre F, Pedroso L M, Lavelle E C , et al. Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles. International Journal of Pharmaceutics, 2018,552(1-2):7-15.
|
[39] |
Oleszycka E, Lavelle E C . Immunomodulatory properties of the vaccine adjuvant alum. Current Opinion in Immunology, 2014,28:1-5.
|
[40] |
Liu H, Jia Z, Yang C , et al. Aluminum hydroxide colloid vaccine encapsulated in yeast shells with enhanced humoral and cellular immune responses. Biomaterials, 2018,167:32-43.
|
[41] |
Silva A, Soema P C, Slütter B , et al. PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Human Vaccines, 2016,12(4):1056-1069.
|
[42] |
Lin Y F, Lee Y H, Hsu Y H , et al. Resveratrol-loaded nanoparticles conjugated with kidney injury molecule-1 as a drug delivery system for potential use in chronic kidney disease. Nanomedicine, 2017,12(22):2741-2756.
|
[43] |
Meyer R A, Sunshine J C, Perica K , et al. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small, 2015,11(13):1519-1525.
|
[44] |
Chen Q, Xu L, Liang C , et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nature Communications, 2016,7:13193.
|
[45] |
Dong H, Wen Z F, Chen L , et al. Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells. International Journal of Nanomedicine, 2018,13:3353-3365.
|
[46] |
Luo M, Wang H, Wang Z , et al. A STING-activating nanovaccine for cancer immunotherapy. Nature Nanotechnology, 2017,12(7):648-654.
|
[47] |
Qiu L, Valente M, Dolen Y , et al. Endolysosomal-escape nanovaccines through adjuvant-induced tumor antigen assembly for enhanced effector CD8 + T Cell activation . Small, 2018,14(15):1703539.
|
[48] |
Li A W, Sobral M C, Badrinath S , et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nature Materials, 2018,17(6):528-534.
|
[49] |
陈泽锋, 白丽 . 抗肿瘤多肽类药物的来源及其机制的研究进展. 免疫学杂志, 2018,34(12):93-98.
|
|
Chen Z F, Bai L . Research progress in the source and mechanism of the anti-tumor polyprptide drugs. Immunological Journal, 2018,34(12):93-98.
|
[50] |
Qi G B, Gao Y J, Wang L , et al. Self-assembled peptide-based nanomaterials for biomedical imaging and therapy. Advanced Materials, 2018,30(22):e1703444.
|
[51] |
Luo Z, Wu Q, Yang C , et al. A powerful CD8 + T-Cell stimulating D-tetra-peptide hydrogel as a very promising vaccine adjuvant . Advanced Materials, 2017,29(5):1601776.
|
[52] |
Wang H, Luo Z, Wang Y , et al. Enzyme-catalyzed formation of supramolecular hydrogels as promising vaccine adjuvants. Advanced Functional Materials, 2016,26(11):1822-1829.
|
[53] |
张瑾 . 华蟾毒精抗原佐剂效应与增强肿瘤特异性免疫的作用机制研究. 吉林:吉林大学, 2014.
|
|
Zhang J . Research on immunologic adjuvant effects of Cinobufagin and its enhancement function of tumor-specific immune response. Jilin: Jilin University, 2014.
|
[54] |
Kumar P, Bhadauria A S, Singh A K , et al. Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications. Life Sciences, 2018,209:24-33.
|
[55] |
Dash S K, Chattopadhyay S, Tripathy S , et al. Self-assembled betulinic acid augments immunomodulatory activity associates with IgG response. Biomedicine & Pharmacotherapy, 2015,75:205-217.
|
[56] |
苗莹, 刘华强, 王红程 . 原花青素在抗肿瘤机制中的研究进展. 中国临床药理学杂志, 2019,35(14):1541-1544.
|
|
Miao Y, Liu H Q, Wang H C . Research progress of anti-tumor mechanism of proanthocyanidins. The Chinese Journal of Clinical Pharmacology, 2019,35(14):1541-1544.
|
[57] |
张丽娜, 王爽, 刘泽媛 , 等. 四种中药单体作为肿瘤细胞疫苗佐剂的体外筛选研究. 中国免疫学杂志, 2016,32(4):504-508.
|
|
Zhang L N, Wang S, Liu Z Y , et al. Screening tumor vaccine adjuvants from four kinds of Chinese herbal monomer in vitro. Chinese Journal of Immunology, 2016,32(4):504-508.
|
[58] |
朱晓丽 . 人参皂苷药理作用研究进展. 中国药物经济学, 2017,12(12):154-156.
|
|
Zhu X L . Research progress of pharmacological action of Panax Ginseng. China Journal of Pharmaceutical Economics, 2017,12(12):154-156.
|
[59] |
Rivera E, Ekholm Pettersson F, Inganas M , et al. The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccine, 2005,23(46-47):5411-5419.
|
[60] |
Su F, Yuan L, Zhang L , et al. Ginsenosides Rg1 and Re act as adjuvant via TLR4 signaling pathway. Vaccine, 2012,30(27):4106-4112.
|
[61] |
朱喆, 蔡泓志, 李映波 . 中草药提取物作为疫苗佐剂的研究进展. 医学研究杂志, 2018,47(5):7-10.
|
|
Zhu Z, Cai H Z, Li Y B . Research progress of vaccine adjuvants of Chinese herbal. Journal of Medical Research, 2018,47(5):7-10.
|
[62] |
侯玮婷, 罗佳波 . 复方茯苓多糖口服液抗肿瘤作用和免疫调节功能的初步研究. 中药药理与临床, 2017,33(2):78-81.
|
|
Hou W T, Luo J B . The study of the compound poria polysaccharide oral liquid on the antitumor activity and immune regulation function. Pharmacology and Chinese Materia Medica, 2017,33(2):78-81.
|
[63] |
Bo R, Sun Y, Zhou S , et al. Simple nanoliposomes encapsulating Lycium barbarum polysaccharides as adjuvants improve humoral and cellular immunity in mice. International Journal of Nanomedicine, 2017,12:6289-6301.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|